))
A Journey Through Top Articles of 2023 with Dr. Matthew Greenhawt
Manage episode 394305196 series 3514043
Content provided by CSACI. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by CSACI or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
“We cannot be dogmatic about what we say about epinephrine…we need as a field to stop being so dogmatic and do more studies to understand." -- Dr. Matthew Greenhawt
Join us on this eye-opening episode, where we explore the latest breakthroughs in allergy and immunology with Dr. Matthew Greenhawt as he walks us through the pivotal articles of 2023 that are redefining the field.
On this episode:
- Review penicillin allergy delabeling and why this is ready to incorporate into your medical practice.
- Understand the evidence for various atopic dermatitis treatment strategies using evidence-based graded recommendations.
- Discover the potential of dupilumab in its two newest indications - eosinophilic esophagitis and COPD.
- Delve into our latest understanding of epinephrine doses and future directions in research on this fundamental medication.
- Exclusive insights into the EPITOPE trial from the lead author.
This episode is a must-listen for allergists and immunologists looking for a quick literature review and key highlights from 2023. Tune in now for a journey into the heart of the articles that will change the field of allergy!
Links to articles mentioned in the episode:
The Safety of the Direct Drug Provocation Test in Beta-Lactam Hypersensitivity in Children: A Systematic Review and Meta-Analysis - PubMed (nih.gov)
Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis - PubMed (nih.gov)
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts - PubMed (nih.gov)
Optimal dose of adrenaline auto-injector for children and young people at risk of anaphylaxis: A phase IV randomized controlled crossover study - PubMed (nih.gov)
Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy - PubMed (nih.gov)
Visit the Canadian Society of Allergy and Clinical Immunology
Find an allergist using our helpful tool
Find Dr. Hanna on X, previously Twitter, @PedsAllergyDoc or CSACI @CSACI_ca
The Allergist is produced for CSACI by PodCraft Productions
23 episodes
Share
